The cutting-edge weight-loss drug Zepbound can protect obese people from developing type 2 diabetes, a new clinical trial has ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit ...

The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes. While the plan will help more than seven million Americans struggling with ...